Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 109

Similar articles for PubMed (Select 23666564)

1.

Influence of CYP2C19 polymorphism and concomitant antiepileptic drugs on serum clobazam and N-desmethyl clobazam concentrations in patients with epilepsy.

Yamamoto Y, Takahashi Y, Imai K, Miyakawa K, Nishimura S, Kasai R, Ikeda H, Takayama R, Mogami Y, Yamaguchi T, Terada K, Matsuda K, Inoue Y, Kagawa Y.

Ther Drug Monit. 2013 Jun;35(3):305-12. doi: 10.1097/FTD.0b013e318283b49a.

PMID:
23666564
2.

Impact of cytochrome P450 inducers with or without inhibitors on the serum clobazam level in patients with antiepileptic polypharmacy.

Yamamoto Y, Takahashi Y, Imai K, Takahashi M, Nakai M, Inoue Y, Kagawa Y.

Eur J Clin Pharmacol. 2014 Oct;70(10):1203-10. doi: 10.1007/s00228-014-1719-5. Epub 2014 Jul 22.

PMID:
25048408
3.

Effects of CYP2C19 and P450 oxidoreductase polymorphisms on the population pharmacokinetics of clobazam and N-desmethylclobazam in japanese patients with epilepsy.

Saruwatari J, Ogusu N, Shimomasuda M, Nakashima H, Seo T, Tanikawa K, Tsuda Y, Nishimura M, Nagata R, Yasui-Furukori N, Kaneko S, Ishitsu T, Nakagawa K.

Ther Drug Monit. 2014 Jun;36(3):302-9. doi: 10.1097/FTD.0000000000000015.

PMID:
24345815
4.

A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam.

Kosaki K, Tamura K, Sato R, Samejima H, Tanigawara Y, Takahashi T.

Brain Dev. 2004 Dec;26(8):530-4.

PMID:
15533655
5.

Interaction between sulthiame and clobazam: sulthiame inhibits the metabolism of clobazam, possibly via an action on CYP2C19.

Yamamoto Y, Takahashi Y, Imai K, Mogami Y, Matsuda K, Nakai M, Kagawa Y, Inoue Y.

Epilepsy Behav. 2014 May;34:124-6. doi: 10.1016/j.yebeh.2014.03.018. Epub 2014 Apr 17.

PMID:
24742983
6.

Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.

Walzer M, Bekersky I, Blum RA, Tolbert D.

Pharmacotherapy. 2012 Apr;32(4):340-53. doi: 10.1002/j.1875-9114.2012.01028.x. Epub 2012 Mar 15.

PMID:
22422635
7.

Evidence of polymorphic CYP2C19 involvement in the human metabolism of N-desmethylclobazam.

Contin M, Sangiorgi S, Riva R, Parmeggiani A, Albani F, Baruzzi A.

Ther Drug Monit. 2002 Dec;24(6):737-41.

PMID:
12451290
8.

In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism.

Giraud C, Treluyer JM, Rey E, Chiron C, Vincent J, Pons G, Tran A.

Drug Metab Dispos. 2006 Apr;34(4):608-11. Epub 2006 Jan 13.

9.

Interactions between clobazam and standard antiepileptic drugs in patients with epilepsy.

Sennoune S, Mesdjian E, Bonneton J, Genton P, Dravet C, Roger J.

Ther Drug Monit. 1992 Aug;14(4):269-74.

PMID:
1519299
10.

In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19.

Giraud C, Tran A, Rey E, Vincent J, Tréluyer JM, Pons G.

Drug Metab Dispos. 2004 Nov;32(11):1279-86.

11.

Effectiveness of add-on stiripentol to clobazam and valproate in Japanese patients with Dravet syndrome: additional supportive evidence.

Inoue Y, Ohtsuka Y; STP-1 Study Group.

Epilepsy Res. 2014 May;108(4):725-31. doi: 10.1016/j.eplepsyres.2014.02.008. Epub 2014 Feb 19.

PMID:
24630050
12.

Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy.

Contin M, Riva R, Albani F, Baruzzi AA.

Ther Drug Monit. 1999 Dec;21(6):604-8.

PMID:
10604819
13.

Population estimation regarding the effects of cytochrome P450 2C19 and 3A5 polymorphisms on zonisamide clearance.

Okada Y, Seo T, Ishitsu T, Wanibuchi A, Hashimoto N, Higa Y, Nakagawa K.

Ther Drug Monit. 2008 Aug;30(4):540-3. doi: 10.1097/FTD.0b013e31817d842a.

PMID:
18641551
14.

Influence of concomitant antiepileptic drugs on plasma lamotrigine concentration in adult Japanese epilepsy patients.

Yamamoto Y, Inoue Y, Matsuda K, Takahashi Y, Kagawa Y.

Biol Pharm Bull. 2012;35(4):487-93.

15.

Stiripentol: an example of antiepileptic drug development in childhood epilepsies.

Nabbout R, Chiron C.

Eur J Paediatr Neurol. 2012 Sep;16 Suppl 1:S13-7. doi: 10.1016/j.ejpn.2012.04.009. Epub 2012 Jun 12. Review.

PMID:
22695038
16.

Impact of CYP2C19 polymorphisms on the efficacy of clobazam therapy.

Seo T, Nagata R, Ishitsu T, Murata T, Takaishi C, Hori M, Nakagawa K.

Pharmacogenomics. 2008 May;9(5):527-37. doi: 10.2217/14622416.9.5.527.

PMID:
18466100
17.

Interactions of clobazam with conventional antiepileptics in children.

Theis JG, Koren G, Daneman R, Sherwin AL, Menzano E, Cortez M, Hwang P.

J Child Neurol. 1997 Apr;12(3):208-13.

PMID:
9130097
18.

[Association between genetic polymorphisms of CYP2C19 and CYP2C9 and phenytoin serum concentration].

Huang Y, Yang JF, Qi XL, Wang YQ, Wang WZ, Chen B.

Zhonghua Yi Xue Za Zhi. 2004 Oct 17;84(20):1686-9. Chinese.

PMID:
15569425
19.

Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms.

Hung CC, Lin CJ, Chen CC, Chang CJ, Liou HH.

Ther Drug Monit. 2004 Oct;26(5):534-40.

PMID:
15385837
20.

Unusual side-effects due to clobazam: a case report with genetic study of CYP2C19.

Parmeggiani A, Posar A, Sangiorgi S, Giovanardi-Rossi P.

Brain Dev. 2004 Jan;26(1):63-6.

PMID:
14729419
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk